Industry News

Pharmaceutical Industry News

Vifor Pharma is letting go of 55…

October 8th, 2025|Fierce Pharma|

Vifor Pharma is letting go of 55 employees who report to the Swiss company’s primary U.S. office in King of Prussia, Pennsylvania, just outside Philadelphia, according to a Worker Adjustment and Retraining Notification Act report

A U.S. advertising self-regulatory…

October 8th, 2025|Fierce Pharma|

A U.S. advertising self-regulatory body has told Galderma to drop or change a claim about how quickly Nemluvio provides itch relief, triggered by a complaint from competitor Sanofi.

Boehringer’s Jascayd is the first…

October 7th, 2025|Fierce Pharma|

Boehringer's Jascayd is the first new drug to break into the idiopathic pulmonary fibrosis field in more than a decade, following in the footsteps of the company's 2014-approved blockbuster Ofev.

This year has brought a range of…

October 7th, 2025|Fierce Pharma|

This year has brought a range of challenges for biopharma companies and their leaders, including on-and-off tariff threats and President Donald Trump's arm-twisting around overseas drug spending. Now, new data show how industry leaders are

A Los Angeles court found Johnson…

October 7th, 2025|Fierce Pharma|

A Los Angeles court found Johnson & Johnson liable in a case brought by a woman who died from mesothelioma in 2021. With its decision, a jury ordered the company to pay $966 million to

Novartis polled more than 3,000…

October 7th, 2025|Fierce Pharma|

Novartis polled more than 3,000 women to gauge how their thoughts and feelings about their breasts impact their breast health, discovering five findings that could offer insight into what's needed to encourage more conversations on

AbbVie is going back to school to…

October 7th, 2025|Fierce Pharma|

AbbVie is going back to school to support patients with inflammatory bowel disease, enrolling “Abbott Elementary” star Tyler James Williams for a new campaign aimed at sparking deeper conversations about long-term IBD treatment goals.

Less than two months after OXB…

October 7th, 2025|Fierce Pharma|

Less than two months after OXB revealed a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy manufacturer has purchased a viral vector plant in North Carolina from National Resilience

Join Fierce Pharma as we sit down…

October 7th, 2025|Fierce Pharma|

Join Fierce Pharma as we sit down with industry innovators to explore the most impactful strategies, cutting-edge insights, and collaborative approaches shaping the future of pharma engagement.

The specialty pharmacy industry is…

October 7th, 2025|Fierce Pharma|

The specialty pharmacy industry is in a state of transformation, fueled by the rise of complex, innovative therapies and the critical need for more robust patient support.

Gilead Sciences has struck accords…

October 6th, 2025|Fierce Pharma|

Gilead Sciences has struck accords with Lupin, Cipla and Laurus Labs to delay the entry of any Biktarvy copycats in the U.S. until April 1, 2036. Gilead had previously estimated that Biktarvy’s U.S. market exclusivity

Even as President Donald Trump…

October 6th, 2025|Fierce Pharma|

Even as President Donald Trump directed the FDA in early September to begin cracking down on direct-to-consumer pharmaceutical advertising, spending on TV drug ads still ratcheted up compared to the preceding few months.

A California judge has ruled that…

October 6th, 2025|Fierce Pharma|

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that covered a process

Amgen has joined the wave of major…

October 6th, 2025|Fierce Pharma|

Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices.